- Home
- / Virax Biolabs
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Virax Biolabs financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$2.2
2024-10-29
Market Capitalization
$9.5 M
2024-10-29
Revenue
$6 K
FY, 2025
CreditSafe Score
?
Score changed on Jun 11, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 100.0K | 124.0K | 9.0K | 156.0K | 6.0K | |
| Cost of goods sold | 54.0K | 133.0K | 10.0K | 51.0K | 59.0K | |
| Gross profit | 46.0K | (9.0K) | (1.0K) | 105.0K | (53.0K) | |
| Gross profit margin, % | 46.0% | -7.3% | -11.1% | 67.3% | -883.3% | |
| Operating expense total | 697.0K | 635.0K | 1.7M | 5.7M | 6.2M | 5.8M |
| Depreciation and amortization | 445.0K | 267.0K | ||||
| EBITDA | (651.0K) | (644.0K) | (1.7M) | (5.7M) | (6.1M) | (5.9M) |
| EBITDA margin, % | -651.0% | -519.4% | -63700.0% | -3878.8% | -98266.7% | |
| EBIT | (649.0K) | (644.0K) | (1.7M) | (5.4M) | (6.7M) | (6.1M) |
| EBIT margin, % | -649.0% | -519.4% | -60466.7% | -4302.6% | -102433.3% | |
| Interest expense | 90.0K | 29.0K | 15.0K | 15.0K | 27.0K | 58.0K |
| Pre tax profit | (739.0K) | (673.0K) | (1.7M) | (5.5M) | (6.7M) | (6.2M) |
| Income tax expense | (137.0K) | |||||
| Net Income | (739.0K) | (673.0K) | (1.7M) | (5.5M) | (6.7M) | (6.1M) |